These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 38073551

  • 21. Characteristics of Clostridium difficile isolates and the burden of hospital-acquired Clostridium difficile infection in a tertiary teaching hospital in Chongqing, Southwest China.
    Dai W, Yang T, Yan L, Niu S, Zhang C, Sun J, Wang Z, Xia Y.
    BMC Infect Dis; 2020 Apr 15; 20(1):277. PubMed ID: 32293302
    [Abstract] [Full Text] [Related]

  • 22. Perils and pitfalls of probiotic quasi-experimental studies for primary prevention of Clostridioides difficile infection: A review of the evidence.
    McFarland LV, Johnson SB, Evans CT.
    Am J Infect Control; 2021 Mar 15; 49(3):375-384. PubMed ID: 32791261
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Is primary prevention of Clostridium difficile infection possible with specific probiotics?
    Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, Low DE, Goldstein EJ.
    Int J Infect Dis; 2012 Nov 15; 16(11):e786-92. PubMed ID: 22863358
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P.
    Drugs; 2022 Oct 15; 82(15):1527-1538. PubMed ID: 36287379
    [Abstract] [Full Text] [Related]

  • 29. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
    Finn E, Andersson FL, Madin-Warburton M.
    BMC Infect Dis; 2021 May 19; 21(1):456. PubMed ID: 34016040
    [Abstract] [Full Text] [Related]

  • 30. Prescribed probiotic usage to prevent Clostridioides difficile infection among older patients receiving antibiotics: A retrospective cohort study.
    Mori N, Katsumata T, Takahashi T.
    J Infect Chemother; 2023 Sep 19; 29(9):833-837. PubMed ID: 37211085
    [Abstract] [Full Text] [Related]

  • 31. Temporal change of risk factors in hospital-acquired Clostridioides difficile infection using time-trend analysis.
    Song J, Cohen B, Zachariah P, Liu J, Larson EL.
    Infect Control Hosp Epidemiol; 2020 Sep 19; 41(9):1048-1057. PubMed ID: 32468975
    [Abstract] [Full Text] [Related]

  • 32. Clostridioides difficile infection (CDI) during the COVID-19 pandemic.
    Spigaglia P.
    Anaerobe; 2022 Apr 19; 74():102518. PubMed ID: 35063599
    [Abstract] [Full Text] [Related]

  • 33. Incidence, epidemiology and control of Clostridium difficile infection in a tertiary care private hospital in India.
    Singhal T, Shah S, Tejam R, Thakkar P.
    Indian J Med Microbiol; 2018 Apr 19; 36(3):381-384. PubMed ID: 30429391
    [Abstract] [Full Text] [Related]

  • 34. Sustained reductions in unnecessary antimicrobial administration and hospital Clostridioides difficile rates via stewardship in a nonacademic setting.
    Gaffin N, Spellberg B.
    Infect Control Hosp Epidemiol; 2023 Mar 19; 44(3):491-493. PubMed ID: 34915961
    [Abstract] [Full Text] [Related]

  • 35. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016-2017 data from US hospitals.
    Tabak YP, Srinivasan A, Yu KC, Kurtz SG, Gupta V, Gelone S, Scoble PJ, McDonald LC.
    Infect Control Hosp Epidemiol; 2019 Nov 19; 40(11):1229-1235. PubMed ID: 31522695
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Post-Discharge Clostridioides difficile Infection after Arthroplasties in Poland, Infection Prevention and Control as the Key Element of Prevention of C. difficile Infections.
    Jachowicz E, Pac A, Różańska A, Gryglewska B, Wojkowska-Mach J.
    Int J Environ Res Public Health; 2022 Mar 08; 19(6):. PubMed ID: 35328843
    [Abstract] [Full Text] [Related]

  • 38. Trends in facility-level rates of Clostridioides difficile infections in US hospitals, 2019-2020.
    Rose AN, Baggs J, Kazakova SV, Guh AY, Yi SH, McCarthy NL, Jernigan JA, Reddy SC.
    Infect Control Hosp Epidemiol; 2023 Feb 08; 44(2):238-245. PubMed ID: 35586888
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.
    Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE.
    Am J Gastroenterol; 2010 Jul 08; 105(7):1636-41. PubMed ID: 20145608
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.